Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma

Naoki Yajima, Ryuya Yamanaka, Takashi Mine, Naoto Tsuchiya, Jumpei Homma, Masakazu Sano, Terukazu Kuramoto, Yayoi Obata, Nobukazu Komatsu, Yoshimi Arima, Akira Yamada, Minoru Shigemori, Kyogo Itoh, Ryuichi Tanaka

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Purpose: The primary goal of this phase I study was to assess the safety and immunologic responses of personalized peptide vaccination for patients with advanced malignant glioma. Experimental Design: Twenty-five patients with advanced malignant glioma (8 grade 3 and 17 grade 4 gliomas) were evaluated in a phase I clinical study of a personalized peptide vaccination. For personalized peptide vaccination, prevaccination peripheral blood mononuclear cells and plasma were provided to examine cellular and humoral responses to 25 or 23 peptides in HLA-A24+ or HLA-A2+ patients, respectively; then, only the reactive peptides (maximum of four) were used for in vivo administration. Results: The protocols were well tolerated with local redness and swelling at the injection site in most cases. Twenty-one patients received more than six vaccinations and were evaluated for both immunologic and clinical responses. Increases in cellular or humoral responses specific to at least one of the vaccinated peptides were observed in the postvaccination (sixth) samples from 14 or 11 of 21 patients, respectively. More importantly, significant levels of peptide-specific IgG were detected in the postvaccination tumor cavity or spinal fluid of all of the tested patients who showed favorable clinical responses. Clinical responses were 5 partial responses, 8 cases of stable disease, and 8 cases of progressive disease. The median overall survival for patients with recurrent glioblastoma multiforme in this study (n = 17) was 622 days. Conclusions: Personalized peptide vaccinations were recommended for the further clinical study to malignant glioma patients.

Original languageEnglish
Pages (from-to)5900-5911
Number of pages12
JournalClinical Cancer Research
Volume11
Issue number16
DOIs
Publication statusPublished - 2005 Aug 15
Externally publishedYes

Fingerprint

Glioma
Vaccination
Peptides
HLA-A24 Antigen
HLA-A2 Antigen
Glioblastoma
Blood Cells
Research Design
Immunoglobulin G
Safety
Injections
Survival
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Yajima, N., Yamanaka, R., Mine, T., Tsuchiya, N., Homma, J., Sano, M., ... Tanaka, R. (2005). Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clinical Cancer Research, 11(16), 5900-5911. https://doi.org/10.1158/1078-0432.CCR-05-0559

Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. / Yajima, Naoki; Yamanaka, Ryuya; Mine, Takashi; Tsuchiya, Naoto; Homma, Jumpei; Sano, Masakazu; Kuramoto, Terukazu; Obata, Yayoi; Komatsu, Nobukazu; Arima, Yoshimi; Yamada, Akira; Shigemori, Minoru; Itoh, Kyogo; Tanaka, Ryuichi.

In: Clinical Cancer Research, Vol. 11, No. 16, 15.08.2005, p. 5900-5911.

Research output: Contribution to journalArticle

Yajima, N, Yamanaka, R, Mine, T, Tsuchiya, N, Homma, J, Sano, M, Kuramoto, T, Obata, Y, Komatsu, N, Arima, Y, Yamada, A, Shigemori, M, Itoh, K & Tanaka, R 2005, 'Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma', Clinical Cancer Research, vol. 11, no. 16, pp. 5900-5911. https://doi.org/10.1158/1078-0432.CCR-05-0559
Yajima, Naoki ; Yamanaka, Ryuya ; Mine, Takashi ; Tsuchiya, Naoto ; Homma, Jumpei ; Sano, Masakazu ; Kuramoto, Terukazu ; Obata, Yayoi ; Komatsu, Nobukazu ; Arima, Yoshimi ; Yamada, Akira ; Shigemori, Minoru ; Itoh, Kyogo ; Tanaka, Ryuichi. / Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 16. pp. 5900-5911.
@article{0e1d7edeabd74d8d8b030201b4f8b22e,
title = "Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma",
abstract = "Purpose: The primary goal of this phase I study was to assess the safety and immunologic responses of personalized peptide vaccination for patients with advanced malignant glioma. Experimental Design: Twenty-five patients with advanced malignant glioma (8 grade 3 and 17 grade 4 gliomas) were evaluated in a phase I clinical study of a personalized peptide vaccination. For personalized peptide vaccination, prevaccination peripheral blood mononuclear cells and plasma were provided to examine cellular and humoral responses to 25 or 23 peptides in HLA-A24+ or HLA-A2+ patients, respectively; then, only the reactive peptides (maximum of four) were used for in vivo administration. Results: The protocols were well tolerated with local redness and swelling at the injection site in most cases. Twenty-one patients received more than six vaccinations and were evaluated for both immunologic and clinical responses. Increases in cellular or humoral responses specific to at least one of the vaccinated peptides were observed in the postvaccination (sixth) samples from 14 or 11 of 21 patients, respectively. More importantly, significant levels of peptide-specific IgG were detected in the postvaccination tumor cavity or spinal fluid of all of the tested patients who showed favorable clinical responses. Clinical responses were 5 partial responses, 8 cases of stable disease, and 8 cases of progressive disease. The median overall survival for patients with recurrent glioblastoma multiforme in this study (n = 17) was 622 days. Conclusions: Personalized peptide vaccinations were recommended for the further clinical study to malignant glioma patients.",
author = "Naoki Yajima and Ryuya Yamanaka and Takashi Mine and Naoto Tsuchiya and Jumpei Homma and Masakazu Sano and Terukazu Kuramoto and Yayoi Obata and Nobukazu Komatsu and Yoshimi Arima and Akira Yamada and Minoru Shigemori and Kyogo Itoh and Ryuichi Tanaka",
year = "2005",
month = "8",
day = "15",
doi = "10.1158/1078-0432.CCR-05-0559",
language = "English",
volume = "11",
pages = "5900--5911",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma

AU - Yajima, Naoki

AU - Yamanaka, Ryuya

AU - Mine, Takashi

AU - Tsuchiya, Naoto

AU - Homma, Jumpei

AU - Sano, Masakazu

AU - Kuramoto, Terukazu

AU - Obata, Yayoi

AU - Komatsu, Nobukazu

AU - Arima, Yoshimi

AU - Yamada, Akira

AU - Shigemori, Minoru

AU - Itoh, Kyogo

AU - Tanaka, Ryuichi

PY - 2005/8/15

Y1 - 2005/8/15

N2 - Purpose: The primary goal of this phase I study was to assess the safety and immunologic responses of personalized peptide vaccination for patients with advanced malignant glioma. Experimental Design: Twenty-five patients with advanced malignant glioma (8 grade 3 and 17 grade 4 gliomas) were evaluated in a phase I clinical study of a personalized peptide vaccination. For personalized peptide vaccination, prevaccination peripheral blood mononuclear cells and plasma were provided to examine cellular and humoral responses to 25 or 23 peptides in HLA-A24+ or HLA-A2+ patients, respectively; then, only the reactive peptides (maximum of four) were used for in vivo administration. Results: The protocols were well tolerated with local redness and swelling at the injection site in most cases. Twenty-one patients received more than six vaccinations and were evaluated for both immunologic and clinical responses. Increases in cellular or humoral responses specific to at least one of the vaccinated peptides were observed in the postvaccination (sixth) samples from 14 or 11 of 21 patients, respectively. More importantly, significant levels of peptide-specific IgG were detected in the postvaccination tumor cavity or spinal fluid of all of the tested patients who showed favorable clinical responses. Clinical responses were 5 partial responses, 8 cases of stable disease, and 8 cases of progressive disease. The median overall survival for patients with recurrent glioblastoma multiforme in this study (n = 17) was 622 days. Conclusions: Personalized peptide vaccinations were recommended for the further clinical study to malignant glioma patients.

AB - Purpose: The primary goal of this phase I study was to assess the safety and immunologic responses of personalized peptide vaccination for patients with advanced malignant glioma. Experimental Design: Twenty-five patients with advanced malignant glioma (8 grade 3 and 17 grade 4 gliomas) were evaluated in a phase I clinical study of a personalized peptide vaccination. For personalized peptide vaccination, prevaccination peripheral blood mononuclear cells and plasma were provided to examine cellular and humoral responses to 25 or 23 peptides in HLA-A24+ or HLA-A2+ patients, respectively; then, only the reactive peptides (maximum of four) were used for in vivo administration. Results: The protocols were well tolerated with local redness and swelling at the injection site in most cases. Twenty-one patients received more than six vaccinations and were evaluated for both immunologic and clinical responses. Increases in cellular or humoral responses specific to at least one of the vaccinated peptides were observed in the postvaccination (sixth) samples from 14 or 11 of 21 patients, respectively. More importantly, significant levels of peptide-specific IgG were detected in the postvaccination tumor cavity or spinal fluid of all of the tested patients who showed favorable clinical responses. Clinical responses were 5 partial responses, 8 cases of stable disease, and 8 cases of progressive disease. The median overall survival for patients with recurrent glioblastoma multiforme in this study (n = 17) was 622 days. Conclusions: Personalized peptide vaccinations were recommended for the further clinical study to malignant glioma patients.

UR - http://www.scopus.com/inward/record.url?scp=23844524128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844524128&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-0559

DO - 10.1158/1078-0432.CCR-05-0559

M3 - Article

VL - 11

SP - 5900

EP - 5911

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 16

ER -